AI Lab-Automation Firm MegaRobo Raises $200M

The round funds overseas expansion as MegaRobo waits in the queue for a Hong Kong listing filed in mid-2025.

Updated on Nov. 19, 2026 in Robotics

Isometric editorial illustration of a single matte articulated robotic arm above an empty tray, in oxblood, deep teal, and cream, evoking automated laboratory work.
MegaRobo Technologies, a Beijing AI-for-Science firm, raised nearly $200 million led by the Oman Investment Authority while it waits in the Hong Kong IPO queue. AI Illustration. Upload story photo >

Live Poll

Do you think AI-driven science companies will make everyday medicines better for people?

MegaRobo Technologies, a Beijing-headquartered AI for Science company, has raised nearly $200 million in a funding round led by investors including the Oman Investment Authority. The round is a funded investment, not a product launch, and the company's proceeds are earmarked for technology and overseas expansion.

Why it matters

The round signals continued investor appetite for AI-driven laboratory automation as a business, with sovereign and cross-border capital entering a niche where AI meets physical experimentation. It also positions MegaRobo for growth across Belt and Road markets while it waits in the queue for a Hong Kong initial public offering filed in mid-2025.

The figures are company-reported funding and client totals rather than independently audited results. MegaRobo's valuation reached $1 billion after the 2022 round, but no post-round valuation for the current raise was given, and the source does not state how the current round's proceeds split between core technology and overseas expansion.

The players

MegaRobo Technologies

A Beijing-based AI for Science company founded in 2016 that automates laboratory workflows for drug screening and target discovery, serving over 1,200 pharmaceutical and biotech clients.

Oman Investment Authority

The sovereign investment vehicle of Oman, which participated in MegaRobo's current funding round.

Goldman Sachs Alternatives

The alternative-investments arm of Goldman Sachs, which co-led MegaRobo's June 2022 Series C round.

The details

MegaRobo describes its AI4S infrastructure as a single system that combines AI, scientific computing, experimental execution, data handling and research-and-development decision-making. In practice, it automates laboratory workflows, which means robotic equipment runs experiments while software plans and analyzes them, speeding up drug screening and target discovery. Target discovery means identifying the specific biological molecules a drug should act on. The company's client base spans more than 1,200 pharmaceutical firms, biotech companies and academic institutions.

Timeline

  1. June 2022: A near-$300 million Series C round, co-led by Goldman Sachs Alternatives, Asia Investment Capital and Granite Asia, lifted the valuation past $1 billion.

  2. Mid-2025: MegaRobo filed for a Hong Kong initial public offering, which remains in the queue.

  3. November 19, 2026: MegaRobo announced the nearly $200 million funding round.

The Tech Race

The round places MegaRobo among AI-for-science companies attracting sovereign and cross-border capital, following its own 2022 Series C that took the valuation past $1 billion. Its Belt and Road expansion plans set it against a field racing to build laboratory automation outside its home market.

The funding does not change any product available today, and the source gives no timeline for new services. Pharmaceutical and academic labs that already use MegaRobo's automation may see expansion, but availability in new regions has not been dated.

The takeaway

The trajectory to watch is whether MegaRobo's overseas expansion across Europe, North America, the Middle East and Asia converts into new client wins. Track the Hong Kong listing filing, which will disclose post-round valuation and revenue detail the current announcement does not give.

What happens next

MegaRobo's Hong Kong initial public offering remains in the queue, and no date for its listing was given in the source.

Further reading

For background on the machines behind this kind of automation, see the Robotics section.

Live Poll

Do you think AI-driven science companies will make everyday medicines better for people?